| Recruiting | PEEL-224, Vincristine and Temozolomide in Pediatric Solid Tumors NCT06721689 | Theodore Laetsch | Phase 1 / Phase 2 |
| Recruiting | Personalized KSX01-TCRT in Patients With Advanced Solid Tumors NCT06150365 | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | EARLY_Phase 1 |
| Recruiting | A Phase Ib Trial of Eribulin in Combination With Irinotecan and Temozolamide in Children With Relapsed or Refr NCT06006273 | M.D. Anderson Cancer Center | Phase 1 |
| Recruiting | KSX01-TCRT Injection Project in Solid Tumors NCT05811975 | TCRx Therapeutics Co.Ltd | EARLY_Phase 1 |
| Recruiting | KSH01-TCRT Solid Tumors NCT05539833 | TCRx Therapeutics Co.Ltd | EARLY_Phase 1 |
| Unknown | Safety and Preliminary Efficacy of BNA035 in Patients With Advanced Solid Tumors NCT05150457 | Binacea Pharma, Inc. | Phase 1 |
| Unknown | Arsenic Trioxide in Refractory Solid Tumors With Rescuable p53 Mutation NCT04869475 | Ruijin Hospital | Phase 2 |
| Terminated | A Study of KB-0742 in Participants With Relapsed or Refractory Solid Tumors Including Platinum Resistant High NCT04718675 | Kronos Bio | Phase 1 / Phase 2 |
| Unknown | MyCustom:Prospective Master Protocol Trial on Precision Medicine Treatment for Refractory Solid Tumors NCT06030869 | Tianjin Medical University Second Hospital | — |
| Completed | Nanoliposomal Irinotecan (Nal-IRI, ONIVYDE®) in Combination With TAS-102 (LONSURF®) in Refractory Solid Tumors NCT03810742 | PharmaEngine | Phase 1 |
| Recruiting | Natural History and Biospecimen Acquisition for Children and Adults With Rare Solid Tumors NCT03739827 | National Cancer Institute (NCI) | — |
| Completed | TCR-engineered T Cells in Solid Tumors (ACTengine IMA201-101) NCT03247309 | Immatics US, Inc. | Phase 1 |
| Completed | Study to Evaluate the Safety and Efficacy of Sunitinib, in Subject With Refractory Solid Tumors NCT02691793 | Samsung Medical Center | Phase 4 |
| Completed | A Study of Intratumoral IMO-2125 in Patients With Refractory Solid Tumors NCT03052205 | Idera Pharmaceuticals, Inc. | Phase 1 |
| Terminated | Safety and Pharmacokinetic Study of IT-141 in Monotherapy in Patients With Advanced Cancer NCT03096340 | Intezyne Technologies, Inc. | Phase 1 |
| Completed | Study to Evaluate the Safety and Efficacy of Sirolimus, in Subject With Refractory Solid Tumors NCT02688881 | Samsung Medical Center | Phase 4 |
| Withdrawn | Study to Evaluate the Safety and Efficacy of Sorafenib, in Subject With Refractory Solid Tumors NCT02691780 | Samsung Medical Center | N/A |
| Completed | Single-arm Study to Evaluate the Safety and Efficacy of Sorafenib, in Subjects With BRAF Mutation Refractory S NCT02450149 | Samsung Medical Center | N/A |
| Completed | Study to Evaluate the Safety and Efficacy of Pazopanib, in Subject With Refractory Solid Tumors NCT02691767 | Samsung Medical Center | N/A |
| Completed | Single-arm Study to Evaluate the Safety and Efficacy of Sunitinib, in Subjects With RET Fusion Positive or FGF NCT02450123 | Samsung Medical Center | N/A |
| Completed | Carfilzomib in Combination With Cyclophosphamide and Etoposide for Children NCT02512926 | Stanford University | Phase 1 |
| Completed | A Study of Eribulin in Combination With Oral Irinotecan for Adolescent and Young Adult Patients With Relapsed NCT02596503 | University of Colorado, Denver | Phase 1 |
| Completed | Single-arm Study to Evaluate the Safety and Efficacy of Pazopanib, in Subjects With FGFR2 Amplification, FGFR2 NCT02450136 | Samsung Medical Center | N/A |
| Completed | A Phase 1a/b Dose Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of OMP-131R10 NCT02482441 | OncoMed Pharmaceuticals, Inc. | Phase 1 |
| Completed | A Dose Escalation and Expansion Study of ASP4132 to Subjects With Advanced Refractory Tumors and Lymphoma NCT02383368 | Astellas Pharma Global Development, Inc. | Phase 1 |
| Completed | A Double-Blind Study in Healthy Volunteers to Assess the Effect of E7080 on the QTc Interval NCT01525394 | Eisai Inc. | Phase 1 |
| Completed | An Open-Label, Dose-Escalation Study of AZD2461 NCT01247168 | AstraZeneca | Phase 1 |
| Withdrawn | A Phase I Trial of AVN944, an IMPDH Inhibitor, in Adults With Advanced Stage Solid Tumors NCT00923728 | Vertex Pharmaceuticals Incorporated | N/A |
| Completed | Safety Study of a Cell Penetrating Peptide (p28) to Treat Solid Tumors That Resist Standard Methods of Treatme NCT00914914 | Dr. Tapas K. Das Gupta | Phase 1 |
| Completed | PK Trial of Sorafenib & Erlotinib in Patients With Refractory Solid Tumors NCT00759928 | SCRI Development Innovations, LLC | Phase 1 |
| Completed | Phase I Study of Bevacizumab and Sorafenib Combined With Low Dose Cyclophosphamide in Patients With Refractory NCT00665990 | St. Jude Children's Research Hospital | Phase 1 |
| Terminated | A Phase 1 Continuous Intravenous Infusion Study of Terameprocol (EM-1421) in Subjects With Refractory Solid Tu NCT00664586 | Erimos Pharmaceuticals | Phase 1 |
| Terminated | A Phase I/Expansion Study of Dasatinib NCT00598091 | Duke University | Phase 1 |
| Completed | A Phase II Study of Epigenetic Therapy to Overcome Chemotherapy Resistance in Refractory Solid Tumors NCT00404508 | National Institute of Cancerología | Phase 2 |
| Completed | Phase 1, Multiple Dose Study of MPC-6827 in Subjects With Refractory Solid Tumors NCT00394446 | Myrexis Inc. | Phase 1 |